Skip to main content

Table 1 Characteristics of the study population

From: Validation of coding algorithms for the identification of patients hospitalized for alcoholic hepatitis using administrative data

 

Entire cohort (n = 228)

Confirmed AH cases (n = 122)

Unconfirmed AH cases (n = 106)

P-value

Age, years

49 (43–55)

49 (42–55)

49 (44–58)

0.33

Male

61 % (138)

60 % (73)

61 % (65)

0.89

Self-reported alcohol consumption, g/day

119 (81–224)

121 (84–233)

112 (56–208)

0.024

Excessive intake a

91 % (208)

100 % (122)

81 % (86)

<0.001

Proportion in the highest intake quartile

25 % (50)

25 % (29)

24 % (21)

0.87

Admission hospital

   

0.69

1

39 % (90)

42 % (51)

37 % (39)

2

30 % (68)

29 % (36)

31 % (32)

3

31 % (70)

29 % (35)

33 % (35)

Year of admission

   

0.16

2008

25 % (56)

22 % (27)

27 % (29)

2009

17 % (40)

15 % (18)

21 % (22)

2010

18 % (41)

17 % (21)

19 % (20)

2011

21 % (48)

21 % (26)

21 % (22)

2012

19 % (43)

25 % (30)

12 % (13)

Biochemical status

    

Maddrey DF

29 (13–52)

45 (26–62)

12 (5–30)

<0.001

MELD

18 (13–23)

21 (18–24)

13 (8–19)

<0.001

Severe b

62 % (142)

80 % (97)

42 % (45)

<0.001

Associated conditions

    

Cirrhosis

25 % (58)

29 % (35)

22 % (23)

0.29

Ascites

27 % (61)

38 % (46)

14 % (15)

<0.001

GI hemorrhage

34 % (77)

39 % (48)

27 % (29)

0.07

Hepatic encephalopathy

2.6 % (6)

2.5 % (3)

2.8 % (3)

1

Malnutrition

3.0 % (7)

4.1 % (5)

1.9 % (2)

0.45

HRS/renal failure

16 % (36)

18 % (22)

13 %(14)

0.37

Pancreatitis

7.9 % (18)

4.9 % (6)

11 % (12)

0.09

Alcohol abuse

36 % (81)

38 % (46)

33 % (35)

0.49

Alcohol dependence

26 % (60)

28 % (34)

25 % (26)

0.65

Alcohol withdrawal

21 % (47)

16 % (19)

26 % (28)

0.05

Mortality

    

In-hospital

5.7 % (13)

7.4 % (9)

3.7 % (4)

0.27

90 days

13 % (29)

17 % (21)

8.5 % (9)

0.045

180 day

17 % (38)

23 % (28)

11 % (12)

0.007

  1. Data are presented as median (IQR) or % (n). DF discriminant function, GI gastrointestinal, HRS hepatorenal syndrome; MELD, Model for End-Stage Liver Disease
  2. a As defined in the Methods
  3. b Severe presentation is characterized by a Maddrey DF of ≥32 and/or the presence of hepatic encephalopathy